Across 8 European countries 163,388 men aged between 55-69 were enrolled in this trial and randomized to either PSA screening or no screening. PSA screening meant a PSA blood test and a rectal exam performed every 4 years, and if the PSA was higher than 3.0 ng/mL a prostate biopsy was performed. The results were that the screened group had a 29% reduced risk of dying from prostate cancer after having being watched for 11 years, as compared to the group who did not have PSA testing. However the overall risk of death was no different. Also, in order to prevent one death from prostate cancer 1055 men needed to have a PSA test and 37 prostate cancers needed to be detected and treated.